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Abstract
Background: Acupuncture is widely used in China to treat functional dyspepsia (FD). However,
its effectiveness in the treatment of FD, and whether FD-specific acupoints exist, are controversial.
So this study aims to determine if acupuncture is an effective treatment for FD and if acupoint
specificity exists according to traditional acupuncture meridians and acupoint theories.
Design: This multicenter randomized controlled trial will include four acupoint treatment groups,
one non-acupoint control group and one drug (positive control) group. The four acupoint
treatment groups will focus on: (1) specific acupoints of the stomach meridian; (2) non-specific
acupoints of the stomach meridian; (3) specific acupoints of alarm and transport points; and (4)
acupoints of the gallbladder meridian. These four groups of acupoints are thought to differ in terms
of clinical efficacy, according to traditional acupuncture meridians and acupoint theories. A total of
120 FD patients will be included in each group. Each patient will receive 20 sessions of acupuncture
treatment over 4 weeks. The trial will be conducted in eight hospitals located in three centers of
China. The primary outcomes in this trial will include differences in Nepean Dyspepsia Index scores
and differences in the Symptom Index of Dyspepsia before randomization, 2 weeks and 4 weeks
after randomization, and 1 month and 3 months after completing treatment.
Discussion: The important features of this trial include the randomization procedures (controlled
by a central randomization system), a standardized protocol of acupuncture manipulation, and the
fact that this is the first multicenter randomized trial of FD and acupuncture to be performed in
China. The results of this trial will determine whether acupuncture is an effective treatment for FD
and whether using different acupoints or different meridians leads to differences in clinical efficacy.
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Background
Functional dyspepsia (FD) is defined as chronic upper
abdominal discomfort or pain, heartburn, early satiety,
nausea, vomiting, abdominal distension and bloating,
without any apparent organic, systemic, or metabolic
pathology to explain these symptoms [1-3]. An epidemio-
logical survey of Western countries showed that the prev-
alence of FD ranges from 11.5% to 14.7% [4]. An
additional study conducted in Tianjin, China, revealed
that 23.29% of the population suffers from FD [5]. A com-
mon and well-recognized public health problem, FD
reduces patient quality of life and increases the economic
burden of medical care [6-11].
Although several classes of drugs (such as proton pump
inhibitors, H2-blockers, and prokinetic drugs) have been
used in clinical practice and some (such as antisecretory
agents or prokinetics) have been effective in placebo-con-
trolled trials, only a small proportion of patients report
sufficient relief from these treatments [12].
The exact etiology of FD remains unclear; thus, it is not
surprising that current treatments for FD are of limited
efficacy and that alternative therapies, including acupunc-
ture, are attractive to both patients and practitioners [13].
Acupuncture has been used in China for many years to
treat gastrointestinal symptoms, including acute and
chronic gastroenteritis, diarrhea, constipation and gas-
troduodenal ulcers [14]. Several randomized controlled
trials (RCTs) have suggested that acupuncture is an effec-
tive treatment for FD, particularly with regards to dyspep-
tic symptoms, belching and anorexia [15-17]. However, it
has been difficult to draw firm conclusions from the
results of these RCTS due to the poor quality of the studies
and the small sample sizes. Therefore, the mechanisms by
which acupuncture treat FD, or whether this therapy
works at all, remain the subject of debate. Therefore, we
have designed a multicenter randomized controlled trial
to address these problems and provide more conclusive
data on the use of acupuncture to treat FD.
The first aim of this trial will focus on the efficacy of acu-
puncture as a treatment for FD. Second, we will attempt to
determine if the efficacy of acupuncture differs with the
type of acupoint, or with the use of acupoints for different
meridians. In a separate paper, we have described the
methods of a clinical trial to examine the role of acupunc-
ture in managing migraines [18], and we are currently
conducting a similar study to assess the efficacy of acu-
puncture as a treatment for migraines.
Methods
Study design
This study will consist of a multicenter randomized con-
trolled trial to compare four acupoint treatment groups
with one non-acupoint control group and one drug (pos-
itive control) group (Figure 1, Table 1). This trial will be
completed in eight hospitals, including the First Affiliated
Hospital of Chengdu University of Traditional Chinese
Medicine (TCM), People's Hospital of Sichuan Province,
No. 4 People's Hospital of Sichuan Province, Affiliated
Hospital of Ningxia Medicine University, First Affiliated
Hospital of Hunan University of TCM, No. 1 People's
Hospital of Wuhan City, TCM Hospital of Hubei Prov-
ince, and the TCM Hospital of Wuhan City.
This trial will include a 4-week treatment period and a 3-
month follow-up period. After randomization, patients
will receive 20 treatments over a period of 4 weeks. Out-
come measurements will be assessed at baseline (i.e., 1
week after subjects are diagnosed with FD), as well as 2
weeks and 4 weeks after randomization, and 1 month and
3 months after conclusion of the treatment phase.
Patients will be informed that they may be assigned to an
acupuncture group, a non-acupoint control group, or the
itopride control group.
This trial will be performed according to the principles of
the Declaration of Helsinki (Version Edinburgh 2000).
The study protocol has been approved by regional ethics
review boards, including the national review board for
clinical drug research, located in the Chengdu University
Hospital of Traditional Chinese Medicine. This study pro-
tocol has permission number 2007 KL-002. All patients
will be asked to provide written consent before enroll-
ment, and will be given ample time to decide if they wish
to participate and sign the consent form. For subjects who
do not want to participate in acupuncture, other treat-
ment options will be available.
Randomization
A central-randomization scheme will be performed at the
Chengdu Good Clinical Practice (GCP) Center, which is
affiliated with the National Clinical Trial Center of Chi-
nese Medicine. This scheme will be used to assign patients
to one of six groups in a 1:1:1:1:1:1 ratio. A permuted-
block randomization procedure, which is automatically
under the control of a central computer system, will be
used to generate an allocation sequence and blind
researchers to the group assignments. Patients who meet
the inclusion criteria will be referred to acupuncturists at
one of the eight study hospitals. The cell phones of all acu-
puncturists will be approved and assigned specific ID
numbers after the acupuncturist completes a special train-
ing course designed for this trial. The acupuncturists will
then use the registered cell phones to send randomization
information to the GCP Center. This randomization
information will include the subject's name in a pinyin
format, the subject's numerical birthday and the subject's
gender. Once the GCP Center computer system receivesTrials 2009, 10:75 http://www.trialsjournal.com/content/10/1/75
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the randomization information, it will randomly assign
patients to an acupoint treatment group or to the control
group. Random numbers and group assignments will be
sent from the GCP Center to the acupuncturists via e-mail
or short message service (SMS). This procedure will ensure
adequate randomization concealment. Patients will be
blinded to the type of acupuncture treatment they receive.
Blinding
As the acupuncturists are responsible for sending rand-
omization information and receiving notices of group
assignments, it would not be practical to blind the acu-
puncturists to treatment allocations and patients' symp-
toms. Additionally, it is not possible to prevent patients
from knowing if they have received acupuncture or ito-
pride treatment. However, it is feasible and ethical to
blind patients to the type of acupuncture they receive. In
addition, we intend to conceal the group assignments
from outcome assessors and our statistician. To assist with
the blinding procedure, we named the groups A, B, C, D,
E, and F in the medical records and case report forms
(CRFs). The specific acupoints (or non-acupoints) will
not be mentioned in these forms.
Eligibility
Inclusion criteria
According to the Rome III Diagnostic Criteria for Func-
tional Gastrointestinal Disorders [19], FD can be diag-
nosed by: (1) meal-induced dyspeptic symptoms (PDS);
and (2) epigastric pain (EPS). Patients diagnosed with
PDS or EPS will be considered for inclusion in this trial.
Patients with one or more of these symptoms (such as
postprandial fullness, early satiation, or epigastric pain or
burning) will be considered patients with dyspepsia.
Accordingly, the inclusion criteria for this study are con-
sistent with the diagnostic criteria for functional dyspep-
sia: aged between 18 and 65 years; not received
gastroenteric dynamic drugs in the 15 days before enroll-
ment; not be taking part in any other clinical trials; and
provide written informed consent.
Table 1: Time to visit and data collection
-1 week 0 week 2 week 4 week 1 month after Treatment 
Phase
3 months after 
Treatment Phase
Baseline Treatment phase Follow-up Phase
Patients
Informed consent X
Medical history X
Physical examination X
Randomization X
Interventions
Specific acupoints of Stomach 
meridians(n = 120)
Non-specific acupoints of 
Stomach meridians(n = 120)
20 sessions of acupuncture at acupoints
Acupoints of Shu and Mu 
acupoints(n = 120)
Acupoints of Gallbladder 
meridians(n = 120)
Comparisons
Non-acupoints control group
(n = 120)
20 sessions of acupuncture at non-acupoints
Itopride control group(n = 120) 50 mg three times daily, 20 days treatment
Outcomesa
NDI X X X X X
SID X X X X X
SF-36 X X X X
Participants safety
Laboratory test X X
Adverse events X X X X X
a. NDI = Nepean Dyspepsia Index; SID = Symptom Index of Dyspepsia; SF-36 = Mos 36-item Short Form Health SurveyTrials 2009, 10:75 http://www.trialsjournal.com/content/10/1/75
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Exclusion criteria
Patients with any of the following conditions will be
excluded: contraindications to itopride, unconsciousness,
history of mental disorders, aggravating malignant
tumors or other serious consumptive disease, susceptibil-
ity to infection and bleeding, serious diseases of the cardi-
ovascular, hepatic, renal, gastrointestinal, hematological
systems, pregnancy or lactation.
Recruitment strategies
Hospital-based recruiting
A large number of patients with FD are currently receiving
healthcare or seeking health advice at hospitals in China.
The host institution developed collaborations with eight
additional hospitals. Primary care physicians at these hos-
pitals are familiar with the study inclusion and exclusion
criteria. Interested patients will be referred to specific
researchers at a study hospital, who will obtain informed
consent and conduct the screening evaluations. Patients
who are willing to participate and who satisfy the inclu-
sion criteria will be introduced to acupuncturists at the
eight hospitals.
Television and newspaper advertisements
Television advertisements will be broadcast on local chan-
nels to promote study participation. Advertisements will
also be published in local newspapers. Printed recruit-
ment posters will be posted in the eight participating hos-
pitals.
Interventions
Interventions were designed according to records in
ancient books and according to recent studies of acupunc-
ture as a treatment for FD. Itopride is a non-acupuncture
treatment option in this trial. The acupuncture protocol
was developed in consensus with Chinese acupuncturists
and acupuncture experts, and is consistent with the
STRICTA (standards for reporting interventions in con-
trolled trials of acupuncture) guidelines for the perform-
ance of acupuncture studies [20].
Rationale for selecting acupoints
The acupuncture treatment protocol is consistent with the
principles of traditional acupuncture theories. These prin-
ciples state that FD is in close proximity to the stomach
meridian; hence, it is reasonable that the acupoint corre-
sponding to the stomach meridian would be most effec-
tive at treating this condition. We also chose to study the
gallbladder meridian because it is anatomically close to
the stomach meridian and therefore may achieve similar
effects. Furthermore, traditional acupuncture theories
maintain that specific points convey specific therapeutic
effects. Thus, the specific acupoint corresponding to the
stomach meridian would be expected to be more effective
than a non-specific acupoint of the same meridian. There-
fore, we selected the most frequently used specific and
non-specific acupoints of the stomach meridian, accord-
ing to the results of a previous review of ancient and mod-
ern literature. According to traditional acupuncture
Trial flow chart Figure 1
Trial flow chart.Trials 2009, 10:75 http://www.trialsjournal.com/content/10/1/75
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theories, the alarm and transport points are considered
specific points. Alarm points (Front-Mu points) are spe-
cific points on the chest or abdomen where the qi of the
respective viscera are concentrated, whereas transport
points (Back-Shu points) are specific points on the back
where the qi of the visceral organs are infused. Both alarm
points and transport points can be used to treat diseases
of specific Zang-Fu organs; for example, Zhongwan
(CV12) and Weishu (BL21) are the alarm and transport
points of the stomach and can be used to treat diseases
related to this organ. Thus, Zhongwan (CV12) and
Weishu (BL21) were selected for use in one of the acu-
puncture treatment groups.
Control groups
Because itopride (Shenzhen Tsinghua Yuanxing Pharma-
ceutical Co., Ltd.) is an effective treatment for FD [21], we
chose to use this drug as a positive control. Patients in the
positive control group will receive similar treatment ses-
sions as acupuncture groups, with administration of 50
mg itopride, three times daily, taken half an hour before
meals [21].
The locations of non-acupoints have been defined in the
literature [22-24]. The locations and manipulations of
acupoints and non-acupoints are shown in Table 2, Figure
2 and Figure 3.
Standardized protocol for acupuncture manipulation
Sterile disposable stainless steel needles (length: 25–40
mm, diameter: 0.25 mm; Hwatuo, Suzhou, China) will be
used on patients in the acupuncture group. Except for the
CV12 acupoint, all acupoints and non-acupoints will be
punctured unilaterally, alternating between the left and
the right to relieve the pain caused from the insertion of
two needles into one acupoint. All acupoint and non-acu-
point control groups will receive electro-stimulation of
acupuncture points. The technique used in the non-acu-
point control group will be the same as treatment groups,
except that no attempt will be made to achieve the Deqi
sensation. After the stimulation of each acupoint or non-
acupoint, auxiliary needles (13 mm in length and 0.18
mm in diameter) will be inserted laterally (proximal
limbs or trunk) into acupoints or non-acupoints to a
depth of 2 mm without manual stimulation. Therefore,
eight needles will be inserted into each patient. Transcuta-
neous electric acupoint stimulation (Han's acupoint nerve
stimulator, HANS, Model LH 200A TENS, Nanjing,
China) will be used for the electro-acupuncture stimula-
tion of every acupoint or non-acupoint after needle inser-
tion. Each acupuncture needle and its auxiliary needle will
be connected to the HANS electrical leads for 30 minutes,
with a stimulation frequency of 2/100 Hz. The stimula-
tion intensity will vary from 0.1 mA to 1.0 mA for all
patients. Electro-acupuncture will be used to ensure that
patients in different acupuncture groups receive the same
extent of stimulation, which will ensure consistency with
regards to performance. Other interventions (such as
moxibustion, cupping and herbs) will not be used.
Patients in the acupuncture treatment groups and the
non-acupoint control group will receive a total of 20 treat-
ments over a 4-week period. The treatments will be
administered once per day, for 5 continuous days, with a
2 day rest interval. This treatment course was designed
according to the acupuncture protocol used in Chinese
Locations of acupoints (acupuncture treatment groups) Figure 2
Locations of acupoints (acupuncture treatment 
groups). Acupoints of treatment group 1 are specific acu-
points of Stomach meridian. Acupoints of treatment group 2 
are non-specific acupoints of Stomach meridian. Acupoints of 
treatment group 3 are Alarm and transport points. Acu-
points of treatment group 4 are acupoints of Gallbladder 
meridian.
Locations of non-acupoints (acupuncture control group) Figure 3
Locations of non-acupoints (acupuncture control 
group). Descriptions of locations non-acupoints are availa-
ble at table 2.Trials 2009, 10:75 http://www.trialsjournal.com/content/10/1/75
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clinical acupuncture practice. All acupuncture practition-
ers had undergone at least 8 years of acupuncture training
and were qualified TCM doctors; indeed some were asso-
ciate chief TCM doctors.
Outcome measurements
Patients will be required to complete the Chinese version
of the Nepean Dyspepsia Index (NDI), which has been
translated according to the validated long version of the
Nepean Dyspepsia Index (NDI) [25]. The reliability and
validity of this index were tested in the first phase of the
973 program. Patients will also be asked to complete the
Symptom Index of Dyspepsia and the Mos 36-item Short
Form Health Survey (SF-36). The Symptom Index of Dys-
pepsia focuses on four symptoms, namely postprandial
distension, early satiety, epigastric pain and heartburn.
Each symptom is then graded as asymptomatic (0 point),
mild (1 point), moderate (2 points) or severe (3 points).
The SF-36 is a Chinese version of an English test [2] to
assess the quality of life.
The main outcome measurements in this trial will include
differences in the Nepean Dyspepsia Index (NDI) and the
Symptom Index of Dyspepsia, as measured before rand-
omization, 2 weeks and 4 weeks after randomization, and
1 month and 3 months after the completion of treatment.
Secondary outcome measures will include differences in
the SF-36 before randomization, 4 weeks after randomiza-
tion, and 1 month and 3 months after completing treat-
ment.
Patient safety
All patients will undergo two routine tests of blood, urine
and stool samples, as well as electrocardiogram (ECG)
examination, blood biochemical tests (ALT, AST, BUN,
Scr), and blood glucose (BGlu) tests before randomiza-
tion and immediately after completing treatment. These
tests will help identify and exclude patients with serious
illnesses of the heart, liver and kidney or other severe dis-
ease. Furthermore, the results of these tests will allow the
assessment of risks associated with acupuncture and ito-
pride treatments.
Adverse events caused by acupuncture or itopride, as well
as the remedies for these events, will be documented dur-
ing the treatment and follow-up phases. Such adverse
events may include bleeding, hematoma, fainting, serious
pain and local infection.
Quality control
All acupuncturists are required to undergo special train-
ing, including theoretical and practical lessons, before
participating in the trial. All researchers and clinicians
must understand the purpose and design of this trial, as
Table 2: Details of each group.
Group Acupoints Manipulation
Treatment group 1
(specific acupoints of stomach meridian)
(1) Chongyang(ST42) (1) is punctured perpendicularly 0.3–0.5 cun 
avoiding the artery
(2) Fenglong(ST40) (2) is punctured perpendicularly 1–1.5 cun
(3) Zusanli(ST36) (3) is punctured perpendicularly 1–2 cun
(4) Liangqiu(ST34) (4) is punctured perpendicularly 1–1.2 cun
Treatment group 2
(non-specific acupoints of Stomach meridian)
(1) Tiaokou(ST38) (1) is punctured perpendicularly 1–1.5 cun
(2) Dubi(ST35) (2) is punctured perpendicularly 0.5–1 cun
(3) Yinshi(ST33) (3) is punctured perpendicularly 1–1.5 cun
(4) Futu(ST32) (4) is punctured perpendicularly 1–2 cun
Treatment group 3
(Alarm and transport point)
(1) Weishu(BL21) (1) is punctured obliquely along the spine fo r 
0.5–0.8 cun
(2) Zhongwan(CV12) (2) is punctured perpendicularly 1–1.5 cun
Treatment group 4
(acupoints of Gallbladder meridian)
(1) Qiuxu(GB40) is punctured perpendicularly 0.5–0.8 cun
(2) Guangming(GB37) (2) is punctured perpendicularly 0.5–0.8 cun
(3) Yanglingquan(GB34) (3) is punctured perpendicularly 1–1.5 cun
(4) Waiqiu(GB36) (4) is punctured perpendicularly 0.5–0.8 cun
Non-acupoint group (1) At the medial arm on the anterior border of 
the insertion of the deltoid muscle at the junction 
of deltoid and biceps muscles
(1) is punctured perpendicularly 0.5–1 cun
(2) Half between the tip of the elbow and the 
axillae
is punctured perpendicularly 0.5–1 cun
(3) Ulnar side, half between epicodylus medialis of 
the humerus and ulnar side of the wrist
(3) is punctured perpendicularly 0.5–1 cun
(4) The edge of tibia 1 to 2 cm lateral to the 
Zusanli(ST36) horizontally
(4) is punctured perpendicularly 0.5–1 cunTrials 2009, 10:75 http://www.trialsjournal.com/content/10/1/75
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well as treatment strategies and measures of quality. In
addition, acupuncturists will be trained to use the central
randomization method, complete the CRFs and electro-
CRFs, locate the points and manipulate the needles. Acu-
puncturists who have completed the required training and
have passed an examination will be considered qualified
to assist with this trial. Several trained outcome assessors,
who are blinded to group assignment, will be responsible
for the outcome assessment. Additionally, to maintain
accuracy and quality throughout our clinical study, audits
will be conducted on CRF completion and compliance
with standard operation procedures (SOPs). Finally, qual-
ity control and assurance will be presented in written form
by trained monitors at every participating hospital once a
month. Patient compliance and voluntary withdrawal
from the study (including the reason for withdrawal) will
be fully documented.
Statistical analysis
Sample size was determined prospectively as described in
a previous study that used similar outcome measurements
[21]. The following formula was used to estimate sample
size [26]:
A previous study reported [21] an improvement of 18.0 in
the main outcome NDI index score after treatment with
50 mg itopride. In this study, we anticipate an improve-
ment of no less than 15.0 after acupuncture treatment;
however, there are no previous data regarding NDI scores
for the treatment of FD using acupuncture. Accordingly,
an improvement of 3.0 in the NDI scores of two groups
will be considered minimally significant. Standard devia-
tion was defined as 22.0, according to the previous study
[21]. Calculations were performed using 90% power and
a 5% significance level, resulting in an estimated 120
patients per group. Thus, we must enroll 720 patients in
the six groups, to allow for a 15% withdrawal rate.
The two-sided null hypotheses to be tested include:
(1) The primary outcomes of the acupoint treatment
groups will be equivalent to those of the itopride con-
trol group.
(2) The primary outcomes of the acupoint treatment
groups will be equivalent to those of the non-acupoint
control group.
(3) The primary outcomes of the acupoint treatment
groups will be equivalent to each other.
We will test these hypotheses with a significance level of P
< 0.05. The first step of the analysis will involve compar-
ing the baseline characteristics of the groups. The second
step will be to compare the efficacy of acupoint and ito-
pride in the treatment of FD. The third step will involve
comparing the acupoint treatment group with the non-
acupoint control group. If acupoint treatment is more
effective than non-acupoint treatment in the treatment of
FD, the fourth step will involve comparing the efficacy of
four acupoint treatments.
The analyses of baseline characteristics, as well as the pri-
mary, secondary and other outcomes, are based on the
intention-to-treat (ITT) principle. Data distribution is
expected to be normal owing to the large sample size.
However, any skewed distribution data will be trans-
formed prior to analysis. The repeated measures analysis
will be used in the assessment of different time points
(such as comparing NDI scores before randomization, 2
weeks and 4 weeks after randomization, and 1 month and
3 months after the completion of treatment). Missing val-
ues will be addressed using the method of last observation
carried forward (LOCF) and multiple-imputation. We will
perform sensitivity analysis to determine how these two
methods affect the analytic results. General linear mixed
models, adjusted for clinical site, will be used to study the
effects of treatments on outcomes from baseline to 3
months. Additionally, time-to-event outcomes between
groups will be compared using the log-rank test.
Analysis of data will be performed in a blinded manner by
a designated statistician at the National Clinical Trial
Center of Chinese Medicine (Chengdu GCP Center) in
China. Statistical analyses will be performed using SPSS
15.0 statistics software (SPSS Inc, Chicago, Illinois, USA)
and SAS 9.0 (SAS Institute Inc., Cary, North Carolina,
USA).
Discussion
The  973 program, also known as the National Basic
Research Program of China (NBRPC), is the most impor-
tant basic research program in China and the largest clin-
ical trial investigating the specific physiological effects of
acupoints.
The 973 program consists of two clinical trials that attempt
to clarify the specific effect of acupoints. One study
focuses on the use of acupuncture to treat migraines [18],
whereas the present study focuses on the use of acupunc-
ture to treat FD.
The second part of the 973 program will compare the effi-
cacies of acupoint treatment, non-acupoint treatment and
itopride treatment to determine if acupuncture is an effec-
tive treatment for FD. Furthermore, this study will com-
pare different acupoint treatments to determine if specific
n
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acupoints and non-specific acupoints differ in efficacy. To
our knowledge, this is the largest randomized, blinded
placebo-controlled trial to examine the effects of acupunc-
ture on FD, and one of the first trials to examine the tradi-
tional acupuncture theories of meridians and acupoints.
The theory of TCM and acupuncture strongly suggests that
acupoints and non-acupoints differ in their abilities to
promote specific physiological effects. Acupuncture is
gradually becoming more accepted in countries beyond
China, including in Western countries, as a potential treat-
ment for a wide array of diseases. Indeed, this method has
been used in clinical practice for many years. In recent
years, differences in the "specific" and "non-specific"
effects of acupoints have been examined by some Western
studies [22,27,28]. According to TCM, there are differ-
ences between closely related meridians and other merid-
ians, and there are also differences between specific
acupoints (such as five transport points, alarm points, or
transport points) and non-specific acupoints. Thus, a spe-
cific acupoint for the stomach meridian will be stimulated
in group 1, a non-specific acupoint for the stomach merid-
ian will be stimulated in group 2, alarm and transport
points will be selected in group 3, and the gallbladder
meridian (selected as being representative of other non-
specific disease-related meridians, with a similar specific
acupoint as that used in group 1) was stimulated in group
4. We have examined all relevant acupuncture literature
and have analyzed the frequencies of acupoint during the
first phase of our 973 program. The results indicate that
the most commonly used acupoints are specific acu-
points, such as Zhongwan (CV12, an alarm point),
Zusanli (ST36, five transport points, in the meridian of the
stomach), and Weishu (BL21, a transport point).
Most previous acupuncture trials were performed using
semi-standardized acupuncture protocols. In this trial, we
will restrict the number of acupoints and standardize the
manipulation procedure. These actions have two merits:
First, it is better to blind patients from the type of acu-
puncture they are receiving and second, some confound-
ing factors (such as special rituals of acupuncture) will be
excluded from the analysis, thereby making the acupunc-
ture groups more comparable. However, this study design
has its limitations; for example, the use of limited acu-
points may not be an optimal acupuncture treatment pro-
tocol.
We choose itopride as the drug control because it has been
shown to be an effective drug for FD. Furthermore, ito-
pride caused fewer adverse events than did other gastroin-
testinal prokinetic agents [21]. Therefore, we will attempt
to maintain a non-inferiority design because acupuncture
is associated with no significant side effects. However, our
trial will be limited by our inability to blind patients from
knowing whether they are receiving acupuncture or ito-
pride treatment. This factor may cause a high drop-out
rate in the itopride group because patients will expect to
receive acupuncture treatment when they join the trial. To
prevent the expected high drop-out rate, patients in the
itopride group will be provided with 10 sessions of free
acupuncture after the entire trial has been completed.
Central randomization, a strict and complete form of ran-
domization, will be used in this trial. This method not
only provides rapid determination of group assignment,
but also ensures adequate allocation concealment. In this
trial, we will use transcutaneous electric acupoint stimula-
tion (HANS) to avoid the performance bias generated by
acupuncture practitioners. This method will provide accu-
rate electric stimulation to ensure that every patient
receives the same level of treatment.
We have devoted much effort to defining the non-acu-
point control groups because the locations of non-acu-
point treatments will differ from those described in the
literature. Most Chinese studies have selected non-acu-
points that lie beside the therapeutic acupoint, and half-
way between the two lines or two acupoints [24].
However, reports in the Western literature have recorded
the location of non-acupoints differently [29,30]. In our
previous trial, we designed our two control groups accord-
ing to the consensus of a panel of acupuncture experts.
Thus, the non-acupoint control group in the current study
was defined according to the first phase of our 973 pro-
gram.
Briefly, this trial aims to determine if acupuncture is an
effective treatment for FD. We will also assess differences
in the specific effects of acupoints, as described in tradi-
tional theories. Certain procedures described herein, such
as the randomization procedure, as controlled by central
randomization system, and the standardized protocol for
acupuncture manipulation, can be applied to future acu-
puncture studies.
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